RPL17 and hepatocellular carcinoma: Ren et al. and Kelley et al., respectively, reported that sintilimab (anti-PD-1) plus bevacizumab biosimilar and atezolizumab plus cabozantinib, which is a tyrosine kinases c-Met and VEGFR2 inhibitor, compared with sorafenib, achieved clinically meaningful improvements in OS and PFS for advanced/unresectable HCC [15, 17].